Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib

(2014) Timothy J. Graham et al.   JNCI-Journal of the National Cancer Institute

A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases

(2013) R. J. Lee et al.   CLINICAL CANCER RESEARCH

Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling

(2013) Holly M. Nguyen et al.   PLoS One

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone.

(2012) F. Schimmoller et al.   MOLECULAR CANCER THERAPEUTICS

Computer-aided quantitative bone scan assessment of prostate cancer treatment response

(2012) Matthew S. Brown et al.   NUCLEAR MEDICINE COMMUNICATIONS

Circulating Tumor Cells as Biomarkers in Prostate Cancer

(2011) D. C. Danila et al.   CLINICAL CANCER RESEARCH

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY